NervGen Pharma Corp.
OTC: NGENF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adam H. Rogers
- Employees
- 11
- Headquarters
- Vancouver, Canada
- IPO year
- 2019
- Market cap
- $312.9M
- Website
- https://www.nervgen.com
Loading NGENF…
Loading profile data…Frequently asked questions about NGENF
What does NervGen Pharma Corp. (NGENF) do?
NervGen Pharma Corp., including its affiliated entities, is focused on discovering, advancing, and bringing to market pharmaceutical solutions designed to address medical conditions arising from damage to the nervous system. Their primary experimental compound, NVG-291, is currently undergoing Phase 1 clinical trials to assess its potential effe...
Where does NGENF trade?
NervGen Pharma Corp. (NGENF) trades on the Other OTC.
What sector is NGENF in?
NervGen Pharma Corp. (NGENF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NervGen Pharma Corp.?
Adam H. Rogers is the chief executive officer of NervGen Pharma Corp. (NGENF).
Where is NervGen Pharma Corp. headquartered?
NervGen Pharma Corp. is headquartered in Canada.
Does NGENF pay a dividend?
NervGen Pharma Corp. (NGENF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NGENF go public?
NervGen Pharma Corp. (NGENF) completed its initial public offering in 2019.